このページの翻訳は実験的なもので、現在開発中です。お待ちしております！

Insmed 将来の成長

Future 基準チェック /26

Insmed利益と収益がそれぞれ年間49.5%と38.2%増加すると予測されています。EPS は年間増加すると予想されています。自己資本利益率は 3 年後に-194.3% 50.1%なると予測されています。

主要情報

52.5%

収益成長率

52.7%

EPS成長率

Biotechs 収益成長	29.1%
収益成長率	40.5%
将来の株主資本利益率	-106.6%
アナリストカバレッジ	Good
最終更新日	30 Jul 2024

今後の成長に関する最新情報

Insmed Incorporated (NASDAQ:INSM) Just Released Its Yearly Results And Analysts Are Updating Their Estimates

Feb 25

Recent updates

Insmed Incorporated's (NASDAQ:INSM) 92% Share Price Surge Not Quite Adding Up

May 29

Insmed Strikes Gold With Phase 3 Bronchiectasis Win (Rating Upgrade)

May 28

Insmed Incorporated (NASDAQ:INSM) Just Released Its Yearly Results And Analysts Are Updating Their Estimates

Feb 25

An Intrinsic Calculation For Insmed Incorporated (NASDAQ:INSM) Suggests It's 46% Undervalued

Sep 20

Insmed rises 16% on better-than-expected Q2 result

Aug 04

Is Insmed (NASDAQ:INSM) A Risky Investment?

Jun 24

Insmed: Temporarily Stuck

Feb 19

Is Insmed (NASDAQ:INSM) Using Debt Sensibly?

Dec 11

業績と収益の成長予測

NasdaqGS:INSM - アナリストの将来予測と過去の財務データ ( )USD Millions
日付	収益	収益	フリー・キャッシュフロー	営業活動によるキャッシュ	平均アナリスト数
12/31/2026	953	-373	-267	N/A	13
12/31/2025	529	-653	-610	-628	15
12/31/2024	353	-738	-641	-618	15
3/31/2024	315	-747	-589	-574	N/A
12/31/2023	305	-750	-550	-536	N/A
9/30/2023	281	-724	-524	-509	N/A
6/30/2023	269	-696	-476	-462	N/A
3/31/2023	257	-547	-453	-442	N/A
12/31/2022	245	-482	-410	-400	N/A
9/30/2022	242	-434	-388	-381	N/A
6/30/2022	221	-416	-374	-367	N/A
3/31/2022	201	-438	-348	-340	N/A
12/31/2021	188	-435	-371	-363	N/A
9/30/2021	174	-424	-354	-346	N/A
6/30/2021	171	-375	-336	-329	N/A
3/31/2021	168	-319	-295	-290	N/A
12/31/2020	164	-294	-226	-219	N/A
9/30/2020	169	-245	-215	-197	N/A
6/30/2020	164	-242	-223	-191	N/A
3/31/2020	151	-247	-276	-235	N/A
12/31/2019	136	-254	-293	-251	N/A
9/30/2019	101	-293	-310	-276	N/A
6/30/2019	62	-320	-311	-290	N/A
3/31/2019	32	-330	-278	-264	N/A
12/31/2018	10	-324	-273	-258	N/A
9/30/2018	N/A	-298	-248	-236	N/A
6/30/2018	N/A	-256	-219	-209	N/A
3/31/2018	N/A	-224	-198	-190	N/A
12/31/2017	N/A	-193	N/A	-160	N/A
9/30/2017	N/A	-196	N/A	-169	N/A
6/30/2017	N/A	-188	N/A	-162	N/A
3/31/2017	N/A	-180	N/A	-154	N/A
12/31/2016	N/A	-176	N/A	-147	N/A
9/30/2016	N/A	-139	N/A	-116	N/A
6/30/2016	N/A	-132	N/A	-109	N/A
3/31/2016	N/A	-124	N/A	-105	N/A
12/31/2015	N/A	-118	N/A	-101	N/A
9/30/2015	N/A	-105	N/A	-86	N/A
6/30/2015	N/A	-98	N/A	-83	N/A
3/31/2015	N/A	-92	N/A	-77	N/A
12/31/2014	N/A	-79	N/A	-64	N/A
9/30/2014	N/A	-78	N/A	-66	N/A
6/30/2014	N/A	-71	N/A	-61	N/A
3/31/2014	N/A	-57	N/A	-48	N/A
12/31/2013	N/A	-56	N/A	-47	N/A

アナリストによる今後の成長予測

収入対貯蓄率: INSM今後 3 年間、利益が出ない状態が続くと予測されています。

収益対市場: INSM今後 3 年間、利益が出ない状態が続くと予測されています。

高成長収益: INSM今後 3 年間、利益が出ない状態が続くと予測されています。

収益対市場: INSMの収益 ( 38.2% ) US市場 ( 8.4% ) よりも速いペースで成長すると予測されています。

高い収益成長: INSMの収益 ( 38.2% ) 20%よりも速いペースで成長すると予測されています。

一株当たり利益成長率予想

将来の株主資本利益率

将来のROE: INSM 3 年以内に赤字になると予測されています。

Insmed 将来の成長

Future 基準チェック /26

主要情報

今後の成長に関する最新情報

Price target increased by 8.7% to US$82.63

Price target increased by 7.0% to US$73.44

Price target increased by 25% to US$56.56

Insmed Incorporated (NASDAQ:INSM) Just Released Its Yearly Results And Analysts Are Updating Their Estimates

Insmed Incorporated Provides Sales Guidance for the Full Year 2023 and 2024

Consensus EPS estimates fall by 14%, revenue upgraded

Recent updates

Insmed Incorporated to Report Q2, 2024 Results on Aug 08, 2024

Price target increased by 8.7% to US$82.63

Insmed Incorporated Announces Additional Positive Results from the ASPEN Study

Price target increased by 7.0% to US$73.44

Chief Medical Officer exercised options and sold US$768k worth of stock

Insmed Incorporated has completed a Follow-on Equity Offering in the amount of $649.999989 million.

Chief Financial Officer notifies of intention to sell stock

Price target increased by 25% to US$56.56

Insmed Incorporated has filed a Follow-on Equity Offering in the amount of $500 million.

Insmed Incorporated's (NASDAQ:INSM) 92% Share Price Surge Not Quite Adding Up

Insmed Incorporated Announces Positive Topline Results from Landmark ASPEN Study of Brensocatib in Patients with Bronchiectasis

New major risk - Share price stability

Insmed Strikes Gold With Phase 3 Bronchiectasis Win (Rating Upgrade)

Insmed Incorporated Presents Positive Patient-Reported Outcomes and Microbiologic Data from Phase 3 Arise Study of Arikayce in Patients with NTM Lung Disease at American Thoracic Society 2024 International Conference Plenary Session

President recently sold US$566k worth of stock

President notifies of intention to sell stock

New major risk - Financial position

Insmed Incorporated to Report Q1, 2024 Results on May 09, 2024

Insmed Incorporated, Annual General Meeting, May 13, 2024

Insmed Incorporated to Present New Data from Across its Respiratory Portfolio at the American Thoracic Society 2024 International Conference

President exercised options to buy US$1.4m worth of stock.

Insmed Incorporated (NASDAQ:INSM) Just Released Its Yearly Results And Analysts Are Updating Their Estimates

Full year 2023 earnings: EPS misses analyst expectations

Insmed Incorporated has filed a Follow-on Equity Offering in the amount of $500 million.

Insmed Incorporated to Report Q4, 2023 Results on Feb 22, 2024

President notifies of intention to sell stock

Insmed Incorporated Provides Sales Guidance for the Full Year 2023 and 2024

Chief Medical Officer notifies of intention to sell stock

Insmed Incorporated (NASDAQ:INSM) Investors Are Less Pessimistic Than Expected

President notifies of intention to sell stock

Third quarter 2023 earnings: EPS exceeds analyst expectations

Insmed Incorporated to Report Q3, 2023 Results on Oct 26, 2023

Insmed Incorporated Announces Positive Topline Results from Phase 3 Arise Study of Arikayce® (Amikacin Liposome Inhalation Suspension) in Patients with Ntm Lung Disease Caused by Mac

Consensus EPS estimates fall by 14%, revenue upgraded

Insmed Incorporated (NasdaqGS:INSM) acquired Adrestia Therapeutics Ltd.

Second quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Getting In Cheap On Insmed Incorporated (NASDAQ:INSM) Is Unlikely

Insmed Incorporated to Report Q2, 2023 Results on Aug 03, 2023

Calculating The Intrinsic Value Of Insmed Incorporated (NASDAQ:INSM)

Chief Commercial Officer recently sold US$64k worth of stock

Insmed Incorporated Presents Range of New Study Findings at American Thoracic Society 2023 International Conference

Senior VP recently sold US$68k worth of stock

President exercised options to buy US$4.3m worth of stock.

Insmed Incorporated Unveils New Research Platforms and Capabilities at Investor and Analyst Event

Insmed Incorporated Provides Revenue Guidance for the Full-Year 2023

First quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Would Insmed (NASDAQ:INSM) Be Better Off With Less Debt?

Full year 2022 earnings released: US$3.91 loss per share (vs US$3.88 loss in FY 2021)

A Look At The Fair Value Of Insmed Incorporated (NASDAQ:INSM)

Insmed Incorporated to Report Q4, 2022 Results on Feb 23, 2023

Chief Financial Officer notifies of intention to sell stock

President recently sold US$139k worth of stock

Insufficient new directors

Independent Director recently bought US$796k worth of stock

Insmed Incorporated Provides Revenue Guidance for the Year 2022

Third quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Insmed Incorporated announced that it expects to receive $625 million in funding

Insmed inks financing agreements to raise $500M

Does Insmed (NASDAQ:INSM) Have A Healthy Balance Sheet?

Insmed Incorporated to Report Q3, 2022 Results on Oct 27, 2022

An Intrinsic Calculation For Insmed Incorporated (NASDAQ:INSM) Suggests It's 46% Undervalued

President exercised options and sold US$5.1m worth of stock

Second quarter 2022 earnings: EPS and revenues exceed analyst expectations

Insmed Incorporated Reiterates Revenue Guidance for the Full Year 2022

Insmed rises 16% on better-than-expected Q2 result

Insmed Incorporated to Report Q2, 2022 Results on Aug 04, 2022

Senior VP & General Counsel recently sold US$22k worth of stock

President exercised options and sold US$661k worth of stock

Is Insmed (NASDAQ:INSM) A Risky Investment?